Galapagos’s service division BioFocus DPI will provide SoftFocus compounds for use in Merck Serono’s drug discovery programs. In a separate agreement, BioFocus DPI will perform medicinal chemistry services on an undisclosed Merck Serono program; this represents an extension of a long running collaboration which was last expanded in 2005.
Onno Stolpe, CEO of Galapagos, said: “BioFocus DPI has a long relationship with Merck Serono in medicinal chemistry, which we are pleased to extend again this year. The purchase of BioFocus DPI’s SoftFocus libraries underscores our ability to grow business with clients.”